Real-World Semaglutide Dose Escalation Improves Diabetes Control and Weight

Type 2 Diabetes (T2D) is a chronic metabolic condition affecting millions globally, characterized by high blood sugar levels and often accompanied by obesity. Semaglutide, a GLP-1 receptor agonist, is a highly effective treatment for T2D, known for its significant glycemic control and weight loss benefits. While clinical trials establish its efficacy, real-world data on the effectiveness and safety of escalating once-weekly semaglutide from 0.5 mg to 1.0 mg in routine clinical practice has been less comprehensively documented.

Upon escalation from 0.5 mg to 1.0 mg once-weekly semaglutide, patients demonstrated significant improvements in glycemic control and body weight. The mean HbA1c (a measure of average blood sugar over 2-3 months) decreased by an additional 0.7% (from 7.5% at 0.5 mg to 6.8% at 1.0 mg, p<0.001), with 48% of patients achieving an HbA1c below 7.0%. Mean body weight was further reduced by 3.2 kg (from 92.1 kg to 88.9 kg, p<0.001) after 6 months on the higher dose. Gastrointestinal adverse events, primarily nausea and diarrhea, were reported in 18% of patients during dose escalation, with most being mild and transient, leading to a discontinuation rate of only 4.5%. The most impactful finding was the combined effect: 35% of patients achieved both an HbA1c below 7.0% and at least 5% body weight loss, a 2.1-fold increase compared to the 0.5 mg dose alone.